Q1 2025 Earnings Call Transcript April 16, 2025 Abbott Laboratories beats earnings expectations. Reported EPS is $1.09, ...

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S.

Abbott Laboratories ABT reported first-quarter 2025 adjusted earnings per share (EPS) of $1.09, which beat the Zacks ...

Q1 2025 Earnings Conference Call April 16, 2025 9:00 AM ETCompany ParticipantsMike Comilla - VP, IRRobert Ford - Chairman ...

Analysts are estimating that Abbott Laboratories will report an earnings per share (EPS) of $1.07. The market awaits Abbott ...

A new U.S. Neurological Devices Market Report provides essential insights for CEOs, CFOs, product and marketing managers in the neurology and neurosurgery sectors, helping executives navigate ...

Nexalin has received patent approval from the USPTO for its DIFS method for treating substance use disorders (SUD).

ABT's Structural Heart, Rhythm Management and Neuromodulation businesses are likely to have driven its first-quarter 2025 performance.

Rising Prevalence of Chronic Diseases, Technological Advancements in Pain Therapies, and Aging Global Population Drive Market Expansion ...

Abbott announced the launch of its neuromodulation business’ next-generation delivery system, which will be used to streamline the implantation process for electrodes used as part of its Proclaim DRG ...